Riedel's thyroiditis is a fibrotic condition of the thyroid that requires staged management. When the standard first-line approach fails to achieve its therapeutic goals, a distinct next-line protocol becomes necessary.
The initial approach combines debulking surgery (typically isthmusectomy) with glucocorticoid therapy, supplemented by L-thyroxine replacement and calcium/calcitriol where indicated. Escalation to the next line is warranted when this regimen fails to achieve reduction in the size and consistency of the thyroid mass, resolution of upper airway symptoms, and clearing of dysphonia.
Tamoxifen has been reported as an effective medical intervention at this stage of Riedel's thyroiditis management. The specific combination strategy, regimen details, and monitoring parameters are available in the full structured protocol.
Significant reduction of thyroid mass size and clinical symptoms.
DOI: 10.1210/jc.2011-0617
Tamoxifen has also been reported to be an effective medical intervention in Riedel's thyroiditis as well as other forms of the underlying multifocal fibrosis.
Doses of 10 to 20 mg of tamoxifen either in conjunction with continued prednisone or as monotherapy have been reported in the literature to be successful, significantly reducing mass size and clinical symptoms with apparent persistent effectiveness during continued therapy in most but not all cases reported.
View source ↗